SILPHEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SILPHEN (SILPHEN).
N-acetyl-para-aminophenol (APAP) is a centrally and peripherally acting analgesic and antipyretic. Its mechanism involves inhibition of cyclooxygenase (COX) in the central nervous system, reducing prostaglandin synthesis, and activation of descending serotonergic pathways. It does not significantly inhibit peripheral COX or platelet function.
| Metabolism | Hepatic via conjugation (glucuronidation and sulfation); minor oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI) that is detoxified by glutathione. |
| Excretion | Renal excretion accounts for 65% of the dose as unchanged drug; hepatic metabolism produces inactive glucuronide conjugates (20%), with biliary/fecal elimination comprising the remaining 15%. |
| Half-life | Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolongs to 12-24 hours with creatinine clearance <30 mL/min. |
| Protein binding | 98% bound to albumin. |
| Volume of Distribution | 0.15 L/kg (approx. 10.5 L in 70 kg adult), indicating limited extravascular distribution and high plasma protein binding. |
| Bioavailability | Oral: 90% (with food slightly reducing rate but not extent). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-20 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Duration is dose-dependent and may be extended in hepatic impairment. |
1-2 tablets (25-50 mg diphenhydramine HCl) orally every 4-6 hours as needed; maximum 300 mg/day.
| Dosage form | SYRUP |
| Renal impairment | GFR 10-50 mL/min: administer every 6-8 hours; GFR <10 mL/min: administer every 8-12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | 6-12 years: 12.5-25 mg orally every 4-6 hours, maximum 150 mg/day; >12 years: same as adult. |
| Geriatric use | Initial dose 25 mg orally every 8-12 hours; increase cautiously; avoid prolonged use due to anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SILPHEN (SILPHEN).
| Breastfeeding | SILPHEN is excreted in human breast milk. The milk-to-plasma ratio is approximately 0.8. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. |
| Teratogenic Risk | SILPHEN is contraindicated in pregnancy. It has been shown to cause fetal harm in animal studies. There is a risk of teratogenicity, including structural anomalies and fetal death, particularly during the first trimester. Use during the second and third trimesters may cause fetal toxicity and adverse outcomes. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to acetaminophen or any component; severe hepatic impairment or active liver disease.
| Precautions | Hepatotoxicity risk with doses >4 g/day or in patients with hepatic impairment, alcoholism, or glutathione depletion; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts, liver function tests, and renal function monthly. Assess for signs of fetal distress with ultrasound and non-stress tests starting at 24 weeks gestation. Measure maternal serum drug levels and adjust dose to maintain therapeutic range. |
| Fertility Effects | SILPHEN may impair fertility in females by disrupting ovarian function and menstrual cycles. In males, it may reduce spermatogenesis and sperm motility. These effects are generally reversible upon discontinuation. |